JWH-359

JWH-359 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent and selective CB2 receptor agonist. It is named after the initials of its developer, John W. Huffman, a Clemson University organic chemist.

Chemistry

JWH-359 is part of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as JWH-018 and JWH-073, but differs in that it is a selective agonist of the CB2 receptor, rather than the CB1 receptor.

Pharmacology

As a CB2 receptor agonist, JWH-359 has been found to have potent analgesic and anti-inflammatory effects, without the psychoactive effects typically associated with CB1 receptor agonists. This has led to interest in its potential therapeutic uses, particularly in the treatment of conditions such as chronic pain and inflammatory diseases.

Legal Status

The legal status of JWH-359 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids, which are often associated with illicit use. However, its status may differ depending on the specific laws and regulations in place.

Potential Therapeutic Uses

Due to its selective action on the CB2 receptor, JWH-359 has been investigated for potential therapeutic uses. These include the treatment of chronic pain, inflammatory diseases, and potentially other conditions where modulation of the CB2 receptor could be beneficial. However, further research is needed to fully understand its effects and potential benefits.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman